Jan 19, 2015
Farmak adds Metakos pharmaceutical drug to its oncology portfolio
Farmak, a leader of the domestic pharmaceutical industry, continues extending the oncology line of pharmaceutical products. Thus, Metakos, a new drug, is added to the Company’s portfolio.
This medicinal product is produced in the form of concentrate for solution for infusion (vial, 5 ml, No 1). Metakos contains zoledronic acid as active agent.
The medicinal product is prescribed for:
- preventive treatment of symptoms attributable to osseous lesion (pathologic fractures, constriction injury of vertebrarium, complications after surgical interference and XRT or hypercalcemia caused by malignant tumor) in patients suffering from malignant neoplasms at late stages;
- treatment of hypercalcemia caused by malignant tumor.
It is worth to remind that Farmak’s portfolio of pharmaceutical drugs for treatment of oncological diseases includes such products as Letromara (letrozole as active agent), Androfarm (cyproterone as active agent) and Flutafarm (flutamide as active agent).
More news
Farmak Participates in Medinex 2025 in Baku
Farmak, the largest pharmaceutical manufacturer in Ukraine, showcased its product portfolio at the 27th annual international exhibition of medical innovations Medinex 2025, held in Baku, Azerbaijan. The event gathered around 80 companies from Azerbaijan, Italy, Kazakhstan, China, Poland, and other countries. Medinex serves as a platform for presenting medica...
Nov 04, 2025
